Tepotinib, also known as {MSC2156119|the experimental compound|this agent), represents a promising breakthrough in the targeting of lung malignancy, particularly in patients harboring MET amplifications. This targeted https://joanndox951797.wikicommunications.com/7384568/tepotinib_a_comprehensive_look_into_msc2156119_and_its_potential